ReadR

Read and Share all content headlines, news and trends with ReadR App.

Discover Content : Trends

Discover real-time trending topics, news headlines, twitter trends, google trends, hashtags, and content from different countries in the world.

Top Countries

Select Country:🌐

Worldwide 🌍 | Nigeria 🇳🇬 | South Africa 🇿🇦 | Kenya 🇰🇪 |Brazil 🇧🇷| Canada 🇨🇦 | United Kingdom 🇬🇧| United States 🇺🇸

See all other continents, locations, categories and associated headlines or trending informations here using

America:
Brazil 🇧🇷| Canada 🇨🇦 | United States 🇺🇸

Africa:
Algeria 🇩🇿 | Egypt 🇪🇬 | Ghana 🇬🇭 | Kenya 🇰🇪 |Morocco 🇲🇦| Nigeria 🇳🇬 | South Africa 🇿🇦 |

Middle East:
Turkey 🇹🇷| Cyprus 🇨🇾 |

Europe:
Finland 🇫🇮| Hungary 🇭🇺 |Germany 🇩🇪| Italy 🇮🇹 | Slovakia 🇸🇰 | Switzerland 🇨🇭 | United Kingdom 🇬🇧

Australia/Oceania: 🌐
Australia 🇦🇺|

Asia:
China 🇨🇳 |Japan 🇯🇵|

Show more
Show less

Headline : Mozart Therapeutics to Present Pre-clinical Data on KIR x ICOS CD8 Treg Modulator at Immunology 2024 Meeting

Read more from the original article on here at www.prnewswire.com.





Tags : #mozart #therapeutics #present #preclinical #data #kir #x #icos #cd8 #treg #modulator #immunology #2024 #meeting


No. of Paragraph 20

Findings highlight the novel mechanism of action and potential for therapeutic activity in highly inflammatory autoimmune disease

SEATTLE, May 3, 2024 /PRNewswire/ -- Mozart Therapeutics, the leading developer of CD8 Treg network modulators, today announce the release of new pre-clinical data for their second program, a KIR x ICOS bispecific antibody targeting CD8 regulatory T cells. The data will be presented during the Immunology 2024 meeting, May 3–7 in Chicago, Illinois. 

Presentation highlights demonstrate KIR x ICOS Modulator:

"Our preclinical data underscore the potential of our KIR x ICOS CD8 Treg Modulator as a selective therapeutic approach for highly inflammatory autoimmune diseases, including Crohn's disease and ulcerative colitis. Findings show that the Modulator is selective toward CD8 Treg, efficacious in models of disease, and has an encouraging safety profile," said Dr. Kristine Swiderek, Chief Scientific Officer at Mozart Therapeutics. "The data support further advancement of this promising molecule."

Read more from the original article on here at www.prnewswire.com.


Related Headlines : Mozart Therapeutics to Present Pre-clinical Data on KIR x ICOS CD8 Treg Modulator at Immunology 2024 Meeting (in Google.com):

Hello, below you have a "Web" tab to read more content and an "Image" tab to get related pictures

Example : Trends, Country, News, Jobs, Scholarships, Investment, Business, Politics, Adverts, Fashion, Events, Technology and more.